Regorafenib induces apoptosis and inhibits metastatic potential of human bladder carcinoma cells

29Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

The aim of the present study was to verify the effects of regorafenib on apoptosis and metastatic potential in TSGH 8301 human bladder carcinoma cells in vitro. Cells were treated with different concentration of regorafenib for different periods of time. Effects of regorafenib on cell viability, apoptosis pathways, metastatic potential, and expression of metastatic and anti-apoptotic proteins were evaluated with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay, flow cytometry, cell migration and invasion assay, and western blotting. We found regorafenib significantly reduced cell viability, cell migration and invasion, and expression of metastatic and anti-apoptotic proteins. In addition, regorafenib significantly induced accumulation of sub-G1 phase cells, loss of mitochondrial membrane potential, and expression of active caspase-3 and caspase-8. These results show that regorafenib not only induces apoptosis, but also inhibits metastatic potential in bladder cancer TSGH 8301 cells in vitro.

Cite

CITATION STYLE

APA

Hsu, F. T., Sun, C. C., Wu, C. H., Lee, Y. J., Chiang, C. H., & Wang, W. S. (2017). Regorafenib induces apoptosis and inhibits metastatic potential of human bladder carcinoma cells. Anticancer Research, 37(9), 4919–4926. https://doi.org/10.21873/anticanres.11901

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free